12 Key pharmacokinetic and pharmacodynamic parameters that correlate with the anti-tumor activity of a bispecific PD-L1 conditional 4–1BB agonist

• Quinn Deveraux,
• Heather Kinkead,
• Chelsie Macedo,
• Angelica Sanabria,
• Garrett Cyprus,
• Rajay Pandit,
• James Kalabus,
• Bryan Becklund,
• Florian Sulzmaier,
• John Timmer,
• Brendan Eckelman,
• Analeah Heidt

Affiliations

Quinn Deveraux

Aff653 grid.428605.dFive Prime Therapeutics South San Francisco CA USA

Heather Kinkead

Aff1 grid.21107.350000000121719311OncologyJohns Hopkins University Baltimore MD USA

Chelsie Macedo

Inhibrx, La Jolla, CA, United States

Angelica Sanabria

Inhibrx, La Jolla, CA, United States

Garrett Cyprus

Inhibrx, La Jolla, CA, United States

Rajay Pandit

Inhibrx, La Jolla, CA, United States

James Kalabus

Inhibrx, La Jolla, CA, United States

Bryan Becklund

Inhibrx, La Jolla, CA, United States

Florian Sulzmaier

Inhibrx, La Jolla, CA, United States

John Timmer

Inhibrx, La Jolla, CA, United States

Brendan Eckelman

Inhibrx, La Jolla, CA, United States

Analeah Heidt

Inhibrx, La Jolla, CA, United States